259 related articles for article (PubMed ID: 27045516)
1. The Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and Regulation.
Senarathna SM; Page-Sharp M; Crowe A
PLoS One; 2016; 11(4):e0152677. PubMed ID: 27045516
[TBL] [Abstract][Full Text] [Related]
2. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
3. Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT.
Pham YT; Régina A; Farinotti R; Couraud P; Wainer IW; Roux F; Gimenez F
Biochim Biophys Acta; 2000 Dec; 1524(2-3):212-9. PubMed ID: 11113570
[TBL] [Abstract][Full Text] [Related]
4. Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells.
Oga EF; Sekine S; Shitara Y; Horie T
Am J Trop Med Hyg; 2012 Jul; 87(1):64-9. PubMed ID: 22764293
[TBL] [Abstract][Full Text] [Related]
5. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1200-9. PubMed ID: 12948018
[TBL] [Abstract][Full Text] [Related]
6. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
Elsby R; Surry DD; Smith VN; Gray AJ
Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
[TBL] [Abstract][Full Text] [Related]
7. Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells.
Troutman MD; Thakker DR
Pharm Res; 2003 Aug; 20(8):1192-9. PubMed ID: 12948017
[TBL] [Abstract][Full Text] [Related]
8. Potential P-glycoprotein-mediated herb-drug interaction of phyllanthin at the intestinal absorptive barrier.
Dunkoksung W; Vardhanabhuti N; Jianmongkol S
J Pharm Pharmacol; 2019 Feb; 71(2):213-219. PubMed ID: 30251430
[TBL] [Abstract][Full Text] [Related]
9. Absorptive and Secretory Transport of Selected Artemisinin Derivatives Across Caco-2 Cell Monolayers.
Heyns J; Willers C; Haynes RK; Wong HN; Hamman J; Gouws C
Curr Drug Deliv; 2018; 15(8):1183-1192. PubMed ID: 29779481
[TBL] [Abstract][Full Text] [Related]
10. Reversible inhibition of efflux transporters by hydrogel microdevices.
Levy ES; Samy KE; Lamson NG; Whitehead KA; Kroetz DL; Desai TA
Eur J Pharm Biopharm; 2019 Dec; 145():76-84. PubMed ID: 31639417
[TBL] [Abstract][Full Text] [Related]
11. Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp.
Jin H; Zhu Y; Wang C; Meng Q; Wu J; Sun P; Ma X; Sun H; Huo X; Liu K; Tan A
Biomed Pharmacother; 2020 May; 125():110032. PubMed ID: 32187961
[TBL] [Abstract][Full Text] [Related]
12. Limited P-glycoprotein mediated efflux for anti-epileptic drugs.
Crowe A; Teoh YK
J Drug Target; 2006 Jun; 14(5):291-300. PubMed ID: 16882549
[TBL] [Abstract][Full Text] [Related]
13. Effects of Labrasol and other pharmaceutical excipients on the intestinal transport and absorption of rhodamine123, a P-glycoprotein substrate, in rats.
Lin Y; Shen Q; Katsumi H; Okada N; Fujita T; Jiang X; Yamamoto A
Biol Pharm Bull; 2007 Jul; 30(7):1301-7. PubMed ID: 17603171
[TBL] [Abstract][Full Text] [Related]
14. Regional difference in P-glycoprotein function in rat intestine.
Iida A; Tomita M; Hayashi M
Drug Metab Pharmacokinet; 2005 Apr; 20(2):100-6. PubMed ID: 15855720
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine.
Riffkin CD; Chung R; Wall DM; Zalcberg JR; Cowman AF; Foley M; Tilley L
Biochem Pharmacol; 1996 Nov; 52(10):1545-52. PubMed ID: 8937469
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Potential P-gp Substrates: Main Aspects to Choose the Adequate Permeability Model for Assessing Gastrointestinal Drug Absorption.
da Silva Junior JB; Dezani TM; Dezani AB; dos Reis Serra CH
Mini Rev Med Chem; 2015; 15(10):858-71. PubMed ID: 25963568
[TBL] [Abstract][Full Text] [Related]
17. The effect of two novel cholesterol-lowering agents, disodium ascorbyl phytostanol phosphate (DAPP) and nanostructured aluminosilicate (NSAS) on the expression and activity of P-glycoprotein within Caco-2 cells.
Sachs-Barrable K; Darlington JW; Wasan KM
Lipids Health Dis; 2014 Oct; 13():153. PubMed ID: 25273894
[TBL] [Abstract][Full Text] [Related]
18. Transport characteristics of ebastine and its metabolites across human intestinal epithelial Caco-2 cell monolayers.
Imamura Y; Shimizu K; Yamashita F; Yamaoka K; Takakura Y; Hashida M
Biol Pharm Bull; 2001 Aug; 24(8):930-4. PubMed ID: 11510488
[TBL] [Abstract][Full Text] [Related]
19. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate.
Tolle-Sander S; Rautio J; Wring S; Polli JW; Polli JE
Pharm Res; 2003 May; 20(5):757-64. PubMed ID: 12751631
[TBL] [Abstract][Full Text] [Related]
20. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
